Annexon, Inc. (ANNX)

Market Cap	918.18M
Revenue (ttm)	n/a
Net Income (ttm)	-208.88M
Shares Out	149.06M
EPS (ttm)	-1.39
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,970,185
Open	6.69
Previous Close	6.68
Day's Range	6.15 - 6.76
52-Week Range	1.29 - 6.83
Beta	1.19
Analysts	Strong Buy
Price Target	16.50 (+167.86%)
Earnings Date	Mar 2, 2026

About ANNX

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company’s lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington’s disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) th...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 24, 2020
• Employees: 100
• Stock Exchange: NASDAQ
• Ticker Symbol: ANNX
• Website: https://www.annexonbio.com

Analyst Summary

According to 6 analysts, the average rating for ANNX stock is "Strong Buy." The 12-month stock price target is $16.5, which is an increase of 167.86% from the latest price.

Price Target

$16.5

(167.86% upside)

Analyst Consensus: Strong Buy